Opioid Litigation
RegulationWatch reporting on opioid litigation matters involving US pharmaceutical manufacturers, PBMs and healthcare companies, newest first.
- 340B Program (1)
- Anti-Kickback Statute (3)
- Antitrust (6)
- Controlled Substances Act (3)
- Drug Pricing (8)
- Drug Promotion (1)
- FTC Enforcement (2)
- FTC Report (1)
- False Claims Act (9)
- Marketing Fraud (2)
- Medicare Advantage (1)
- Medicare Negotiation (1)
- Merger Conditions (1)
- Off-Label Promotion (1)
- Opioid Distribution (1)
- Opioid Litigation (4)
- PBM Oversight (1)
- PBM Rebates (7)
- Patent Litigation (1)
- State Enforcement (4)
- Opioid Litigation
Arizona sues Express Scripts and Optum, alleging rebate deals helped drive the opioid epidemic
Arizona Attorney General Kris Mayes filed a consumer fraud lawsuit alleging the two pharmacy benefit managers secured confidential payments from opioid manufacturers, including Purdue Pharma, in exchange for preferred formulary status and fewer utilization controls. Optum called the suit misdirected.
- Opioid Litigation
McKesson is paying up to $7.4 billion over opioid distribution, and admits nothing.
The largest distributor's share of the national settlement runs for 18 years. None of it goes to individual patients.
- Opioid Litigation
AbbVie bought Allergan and inherited an opioid bill of up to $2.37 billion.
Allergan had sold its generic opioid business years earlier. The liability stayed, and the settlement carries no admission.
- Opioid Litigation
Kentucky's opioid case against two PBMs is going to federal court. Its allegations are still unanswered.
A Sixth Circuit ruling settles where the case is heard. Two years after Kentucky sued, no court has tested what Express Scripts and Optum actually did.
